Publications

 

Merrill J, et al. LSM 2018 – Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

View Publication

Ramsey-Goldman R, et al. LSM 2017 • Cell-bound complement activation products in SLE

View Publication

Buyon J, et al. LSM 2016 – Reduction in EC4d and anti-C1q antibodies associate with clinical improvement in SLE.

View Publication

Putterman C, et al. LSM. 2014. Cell_bound complement activation products in systemic lupus erythematosus.

View Publication

Wallace D, et al. LSM. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

View Publication
 

AVISE CTD / AVISE Lupus / AVISE CB-CAPs

AVISE Lupus is indicated for the diagnosis of suspected SLE patients. AVISE CTD is indicated for differential diagnosis of autoimmune connective tissue diseases.

Clinical Validity

Ramsey-Goldman R et al.

ACR Open Rheumatology 2021

Ramsey-Goldman R et al.

Arthritis & Rheumatology 2020

Arriens C et al.

Lupus Science & Medicine 2020

Hui-Yen J et al.

Lupus 2018

Wallace D et al.

Lupus Science & Medicine 2016

Putterman C et al.

Lupus Science & Medicine 2014

Clinical Utility

Alexander RV et al.

Lupus Science & Medicine 2021

Liang E et al.

Lupus Science & Medicine 2020

Wallace D et al.

Lupus Science & Medicine 2019

Mossell J et al.

The Open Rheumatology Journal 2016

Health Economic Outcome Research

Clarke A et al.

ACR Open Rheumatology 2020

Analytical Validity

Dervieux T et al.

Journal of Immunological Methods 2017

Review Articles

Weinstein A et al.

Current Rheumatology Reports 2021

Ramsey-Goldman R et al.

Lupus Science and Medicine 2017

Ahearn J et al.

Expert Review of Clinical Rheumatology 2017

Case Study

Lamichhane D et al.

Lupus 2016

AVISE SLE Monitor / AVISE PC4d

AVISE SLE Monitor is indicated for the ongoing assessment of SLE disease activity. PC4d is indicated for diagnosed SLE patients as a marker associated with thrombosis.

Clinical Validity

Gartshteyn Y et al.

Clinical Immunology 2021

Svenungsson E et al.

Rheumatology 2020

Petri M et al.

Lupus Science & Medicine 2019

Merrill JT et al.

Lupus Science & Medicine 2018

Mahler M et al.

Journal of Immunology Research 2017

Buyon J et al.

Lupus Science & Medicine 2016

Orbai AM et al.

Lupus 2015

Kao AH et al.

Transitional Stroke Research 2014

Akhter E et al.

Lupus 2012

Kao A et al.

Arthritis & Rheumatology 2010

Avise MTX is indicated for RA patients receiving Methotrexate therapy as an objective measure of therapeutic exposure.

Clinical Validity

Dervieux T et al.

Annals of the Rheumatic Diseases 2019

Takahashi C et al.

RMD Open 2017

Dervieux T et al.

Annals of the Rheumatic Diseases 2013

Dervieux T et al.

Rheumatology 2010

Dervieux T et al.

Arthritis & Rheumatology 2006

Dervieux T et al.

Annals of the Rheumatic Diseases 2005

Analytical Validity

Brady K et al.

The Journal of Applied Laboratory Medicine 2019

Review Articles

Braun J et al.

Therapeutic Advances in Musculoskeletal Disease 2011

Kremer J et al.

Arthritis & Rheumatology 2004

AVISE HCQ is indicated for SLE patients receiving Hydroxychloroquine therapy as an objective measure of drug exposure.

Clinical Validity

Petri M et al.

Arthritis & Rheumatology 2020

Costedoat-Chalumeau N et al.

Clinical Pharmacology and Therapeutics 2019

Costedoat-Chalumeau N et al.

Annals of the Rheumatic Diseases 2013

Analytical Validity

Qu Y et al.

Journal of Pharmaceutical and Biomedical Analysis 2017

AVISE HCQ Review Articles

Durcan L et al.

The Journal of Rheumatology 2015

Anti-Carbamylated Protein Antibodies (Anti-CarP)

Weinstein A et al.

The Journal of Rheumatology 2019

Truchetet M et al.

Arthritis & Rheumatology 2017

Shi J et al.

PNAS 2011

Selected Abstracts

Sun K et al.

Arthritis & Rheumatology 2021

Cell-bound Complement Activation Products (CB-CAPs) predicts Type 1 SLE activity

Rogers J et al.

Arthritis & Rheumatology 2021

O'Malley T et al.

Arthritis & Rheumatology 2021

Alexander R et al.

Arthritis & Rheumatology 2021

Petri M et al.

Arthritis & Rheumatology 2020

Gartshteyn Y et al.

Arthritis & Rheumatology 2020

Petri M et al.

Arthritis & Rheumatology 2020

Dervieux T et al.

Arthritis & Rheumatology 2019

Shi J et al.

Arthritis & Rheumatology 2018

Dervieux T et al.

Arthritis & Rheumatology 2017

Wallace D et al.

Arthritis & Rheumatology 2017